18.02.2019 • News

Mitsui, ISK Take Stakes in Brazil’s Ourofino

Mitsui, ISK Take Stakes in Brazil’s Ourofino (c) Ourofino
Mitsui, ISK Take Stakes in Brazil’s Ourofino (c) Ourofino

Japanese companies Mitsui & Co. and Ishihara Sangyo Kaisha (ISK) have signed a binding agreement to jointly acquire a 25% stake in Brazilian agrochemical company, Ouro Fino Quimica. Mitsui will take a 20% share of Ourofino, with ISK taking 5%.

Completion of the transaction is subject to customary conditions and regulatory approval. The companies have not revealed financial details.

Located in Uberaba, Minas Gerais, Ourofino manufactures a range of agrochemicals, including fungicides, herbicides and insecticides.

Mitsui said it intends with ISK to contribute to expanding Ourofino’s business in Brazil, which is the world’s largest market for crop protection products, accounting for about 20% of global demand. Ourofino will benefit from access to Mitsui’s assets around the world and will include ISK’s products, which include herbicides, fungicides, insecticides and nematicides, into its portfolio.

As part of its medium-term management plan, Mitsui has identified nutrition and agriculture as one of its key new growth areas. The Tokyo-headquartered group distributes agrochemicals and agricultural supplies in Europe through wholly owned subsidiary Mitsui AgriScience International Europe and in the US through its fully owned biopesticides division Certis USA.

Company

Logo:

Mitsui Chemicals Europe GmbH

Oststr. 34
40211 Düsseldorf
Germany

Company contact







Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read